针对发病率逐年增高的丙型肝炎,目前主要依靠利巴韦林和干扰素的联合用药加以控制症状,但在治疗同时伴有明显不良反应,而且至今仍无法治愈.因此,临床上迫切需要研发出新型抗丙型肝炎病毒(HCV)药物,并且随着HCV生物学研究的快速发展,对HCV的感染和复制有了更深入的了解,加速了新药研发进程.本文综述了抗HCV药物作用靶标和新型小分子抑制剂,重点对其抑制剂的化学结构、抗HCV活性和构效关系进行了相关总结.%In recent years,the infection caused by hepatitis C virus (HCV)is increasing.The current therapy is in combination of pegylated interferon injection and ribavirin oral administration,while it is not much effective with lots of side effects.Thus,there is an emergent need to develop novel anti-HCV agents.With the development of HCV biology,there is in-depth knowledge about HCV infection and replication,which is important to accelerate the process of new drug development.This review summarized recent progress of antiHCV drug targets and small molecule inhibitors.In particular,chemical structures,anti-HCV activity and structure-activity relationships of HCV inhibitors are focused on.
展开▼